Figure 3.

Evaluation of MHC Class I Antigen Presentation

(A) BMDCs were treated with several types of KALA-OVA-LPs (DOPE or EPC as a helper lipid), modified with the KALA peptide (1, 3, 5, 7, or 9 mol% of total lipid) or R8-OVA-LPs (DOPE as a helper lipid, modified with R8 peptide (5 mol% of total lipid) at a dose of 10 μM of lipid. After 5 hr, the treated cells were co-cultured with a B3Z T cell hybridoma, specific for the OVA_257–264 epitope in the context of K^{b, 41} for 15 hr at 37°C. The co-cultured cells were lysed and incubated with chrolophenol red β-D-galactopyranoside buffer for 4 hr at 37°C. The absorbance at 595 nm was used as an index for antigen presentation activity. Data are mean + SD (n = 3). Statistical analyses were performed using one-way ANOVA, followed by the Dunnett test. **p < 0.01 versus 5 mol% KALA-OVA-LPs composed of DOPE. N.S., not significant. (B) BMDCs were treated with the KALA-OVA-LPs or R8-OVA-LPs at several doses. Data are mean ± SD (n = 3). Statistical analyses were performed using Student’s t test. **p < 0.01.